ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,328 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Phase 2Lymphoma, Large B-Cell, Diffuse

Zilovertamab vedotinRituximabCyclophosphamide+6 more

Merck Sharp & Dohme LLC594 participants140 sites · United States, Belgium, GermanyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Phase 2Large Cell Lymphoma, DiffuseRelapsed CancerRefractory Cancer

AutoSCT OR CAR T-cell TherapyGDPEpcoritamab

Dipenkumar Modi35 participants4 sites · United StatesCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD

Phase 2Graft vs Host Disease

Fecal microbiota transplantation (FMT)

Chang Gung Memorial Hospital35 participants1 site · TaiwanCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Phase 1Phase 2Advanced Solid TumorsPARP Inhibitor

SRP1020

Shanghai SciBrunch Therapeutics Co., Ltd.210 participants2 sites · ChinaCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Phase 2Hepatocellular Carcinoma (HCC)

ABSK-011+BSCPlacebo+BSC

Abbisko Therapeutics Co, Ltd141 participants51 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Phase 2Breast CarcinomaChemotherapy-Induced Peripheral NeuropathyColon Carcinoma

Biospecimen CollectionCannabidiolDronabinol+2 more

City of Hope Medical Center120 participants2 sites · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

Phase 2PreleukemiaMyelodysplastic NeoplasmCytopenia

Metformin

Kirsten Grønbæk40 participants1 site · DenmarkCompletes Feb 2026

Compare CT.gov Full analysis →

Recruiting

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Phase 2Non-hodgkin LymphomaHodgkin Lymphoma

DOC Group BPv-COMRAD 1 and 2 Group BPv-R-CYM 1 and 2 Group B+14 more

New York Medical College80 participants3 sites · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Spatially Fractionated Radiotherapy for Tumor Treatment

Phase 1Phase 2Radiotherapy-Induced Immune Priming

spatially fractionated radiotherapy

Xu Zhi-yuan126 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

Phase 2Breast CancerQuality of Life

Accelerated Partial Breast Irradiation (APBI)tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene

UNC Lineberger Comprehensive Cancer Center90 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Phase 2Pancreatic Cancer

SHR-A2102 or/and HRS-4642SHR-A1904 or/and HRS-4642SHR-A1811 or/and HRS-4642+1 more

Fudan University160 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Phase 3Non Small Cell Lung Cancer

D-1553 TabletDocetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.522 participants86 sites · ChinaCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Human Craniomaxillofacial Allotransplantation

Phase 2Facial InjuriesTraumatic Wounds and InjuriesCraniofacial Injuries

Bone marrow cell-based therapy & 1-drug immunosuppression.

Johns Hopkins University15 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Durvalumab and Tremelimumab in Resectable HCC

Phase 2Hepatocellular Carcinoma

Tremelimumab

University Health Network, Toronto28 participants3 sites · Canada, Italy, SpainCompletes Nov 2025

Compare CT.gov Full analysis →

Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3Acute Myeloid Leukemia (AML)

ZiftomenibPlaceboVenetoclax+3 more

Kura Oncology, Inc.1,300 participants115 sites · United States, Australia, BelgiumCompletes Nov 2031

Compare CT.gov Full analysis →

1–15 of 6,328

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,328 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

Phase 2Lymphoma, Large B-Cell, Diffuse

Zilovertamab vedotinRituximabCyclophosphamide+6 more

Merck Sharp & Dohme LLC594 participants140 sites · United States, Belgium, GermanyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Phase 2Large Cell Lymphoma, DiffuseRelapsed CancerRefractory Cancer

AutoSCT OR CAR T-cell TherapyGDPEpcoritamab

Dipenkumar Modi35 participants4 sites · United StatesCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD

Phase 2Graft vs Host Disease

Fecal microbiota transplantation (FMT)

Chang Gung Memorial Hospital35 participants1 site · TaiwanCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Phase 1Phase 2Advanced Solid TumorsPARP Inhibitor

SRP1020

Shanghai SciBrunch Therapeutics Co., Ltd.210 participants2 sites · ChinaCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Phase 2Hepatocellular Carcinoma (HCC)

ABSK-011+BSCPlacebo+BSC

Abbisko Therapeutics Co, Ltd141 participants51 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Phase 2Breast CarcinomaChemotherapy-Induced Peripheral NeuropathyColon Carcinoma

Biospecimen CollectionCannabidiolDronabinol+2 more

City of Hope Medical Center120 participants2 sites · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

Phase 2PreleukemiaMyelodysplastic NeoplasmCytopenia

Metformin

Kirsten Grønbæk40 participants1 site · DenmarkCompletes Feb 2026

Compare CT.gov Full analysis →

Recruiting

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Phase 2Non-hodgkin LymphomaHodgkin Lymphoma

DOC Group BPv-COMRAD 1 and 2 Group BPv-R-CYM 1 and 2 Group B+14 more

New York Medical College80 participants3 sites · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Spatially Fractionated Radiotherapy for Tumor Treatment

Phase 1Phase 2Radiotherapy-Induced Immune Priming

spatially fractionated radiotherapy

Xu Zhi-yuan126 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

Phase 2Breast CancerQuality of Life

Accelerated Partial Breast Irradiation (APBI)tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene

UNC Lineberger Comprehensive Cancer Center90 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Phase 2Pancreatic Cancer

SHR-A2102 or/and HRS-4642SHR-A1904 or/and HRS-4642SHR-A1811 or/and HRS-4642+1 more

Fudan University160 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Phase 3Non Small Cell Lung Cancer

D-1553 TabletDocetaxel injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.522 participants86 sites · ChinaCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Human Craniomaxillofacial Allotransplantation

Phase 2Facial InjuriesTraumatic Wounds and InjuriesCraniofacial Injuries

Bone marrow cell-based therapy & 1-drug immunosuppression.

Johns Hopkins University15 participants1 site · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Durvalumab and Tremelimumab in Resectable HCC

Phase 2Hepatocellular Carcinoma

Tremelimumab

University Health Network, Toronto28 participants3 sites · Canada, Italy, SpainCompletes Nov 2025

Compare CT.gov Full analysis →

Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3Acute Myeloid Leukemia (AML)

ZiftomenibPlaceboVenetoclax+3 more

Kura Oncology, Inc.1,300 participants115 sites · United States, Australia, BelgiumCompletes Nov 2031

Compare CT.gov Full analysis →

1–15 of 6,328